随机、开放、两制剂、两序列、两周期、自身交叉对照设计,评价中国健康受试者在空腹及餐后状态下单次口服萘普生钠片后的生物等效性正式试验
[Translation] A randomized, open-label, two-dose, two-sequence, two-period, self-crossover controlled study to evaluate the bioequivalence of naproxen sodium tablets in Chinese healthy subjects after a single oral dose in the fasting and fed state
以呋欧医药科技(湖州)有限公司提供的萘普生钠片为受试制剂;并以Atnahs Pharma Netherlands B.V.的萘普生钠片为参比制剂,进行人体相对生物利用度和生物等效性评价。
[Translation] Naproxen Sodium Tablets provided by Fuou Pharmaceutical Technology (Huzhou) Co., Ltd. were used as the test preparation, and Naproxen Sodium Tablets from Atnahs Pharma Netherlands B.V. were used as the reference preparation to evaluate the relative bioavailability and bioequivalence in humans.
多巴丝肼片随机、开放、交叉设计在中国健康受试者中的生物等效性正式试验
[Translation] A randomized, open-label, crossover-design formal bioequivalence trial of dopamine tablets in Chinese healthy subjects
以呋欧医药科技(湖州)有限公司的多巴丝肼片为受试制剂;并以上海罗氏制药有限公司的多巴丝肼片为参比制剂,进行人体相对生物利用度和生物等效性评价。
[Translation] The relative bioavailability and bioequivalence of dopamine hydrazide tablets produced by Fuo Pharmaceutical Technology (Huzhou) Co., Ltd. were evaluated in humans, and dopamine hydrazide tablets produced by Shanghai Roche Pharmaceuticals Co., Ltd. were used as the reference preparation.
琥乙红霉素片在健康受试者中随机、开放、单剂量、两制剂、两序列、交叉对照空腹及餐后状态下的生物等效性研究
[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, cross-controlled bioequivalence study of erythromycin ethylsuccinate tablets in healthy subjects under fasting and fed conditions
研究空腹及餐后状态下单次口服受试制剂琥乙红霉素片(规格:0.4g,呋欧医药科技(湖州)有限公司研制,浙江赛默制药有限公司生产)与参比制剂琥乙红霉素片(商品名:E.E.S.400®,规格:400mg,ARBOR PHARMACEUTICALS LLC持证)在健康成年受试者体内的药代动力学,评价空腹及餐后状态下口服两种制剂的生物等效性。
[Translation] The pharmacokinetics of the test preparation erythromycin ethylsuccinate tablets (specification: 0.4g, developed by Fuo Pharmaceutical Technology (Huzhou) Co., Ltd. and produced by Zhejiang Thermo Pharmaceutical Co., Ltd.) and the reference preparation erythromycin ethylsuccinate tablets (trade name: E.E.S.400®, specification: 400mg, licensed by ARBOR PHARMACEUTICALS LLC) were studied in healthy adult subjects after single oral administration in fasting and fed state, and the bioequivalence of the two preparations after oral administration in fasting and fed state was evaluated.
100 Clinical Results associated with Furou Pharmaceutical Technology (Huzhou) Co., Ltd.
0 Patents (Medical) associated with Furou Pharmaceutical Technology (Huzhou) Co., Ltd.
100 Deals associated with Furou Pharmaceutical Technology (Huzhou) Co., Ltd.
100 Translational Medicine associated with Furou Pharmaceutical Technology (Huzhou) Co., Ltd.